Sundaram et al., 2008 - Google Patents

Detoxification depot for β-amyloid peptides

Sundaram et al., 2008

Document ID
15598881508462376008
Author
Sundaram P
Sundaram R
Kasinathan C
Stein S
Publication year
Publication venue
Current Alzheimer Research

External Links

Snippet

Alzheimer's Disease (AD) is caused by the deposition of insoluble and toxic amyloid peptides (Aβ) in the brain leading to memory loss and other associated neurodegenerative symptoms. To date there is limited treatment options and strategies for treating AD. Studies …
Continue reading at www.ingentaconnect.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Similar Documents

Publication Publication Date Title
AU715662B2 (en) Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US7435540B2 (en) PrPSc-selective peptides
US5137873A (en) Substance p and tachykinin agonists for treatment of alzheimer's disease
AU2010315133B2 (en) Positively charged species as binding reagents in the separation of protein aggregates from monomers
AU2006227528A1 (en) Use of ADNF polypeptides for treating peripheral neurotoxicity
EP1214598B1 (en) Screening for inhibitors of "paired helical filaments"
US20110189692A1 (en) Assay for pathogenic conformers
JP4079775B2 (en) Soluble cyclic analog of β-amyloid peptide
US7208475B2 (en) Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
Sundaram et al. Novel Detox Gel Depot sequesters β-Amyloid Peptides in a mouse model of Alzheimer’s disease
WO2008097618A1 (en) Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
Sundaram et al. Detoxification depot for β-amyloid peptides
DK2406279T3 (en) Compositions for prevention and treatment of neurodegenerative diseases
US20050267029A1 (en) Compounds which modulate amyloidogenesis and methods for their identification and use
US20040249122A1 (en) Cationic, amphipathic beta-sheet peptides and uses thereof
Österlund et al. Cell-Penetrating Peptides with Unexpected Anti-Amyloid Properties. Pharmaceutics 2022, 14, 823
AU2003272695B2 (en) PrPsc -Interacting molecules and uses thereof
CN116249903A (en) Inhibitors of alpha-synuclein aggregation and uses thereof
AU759036B2 (en) Modulators of amyloid aggregation
AU769915B2 (en) Modulators of beta-amyloid peptide aggregation comprising D-amino acids
CA2130125A1 (en) Use of amylin in pharmaceutical screens
Porat Aggregation of Amylin in type II diabetes: Molecular recognition elements in islet amyloid assembly and functional inhibition
EP3444264A1 (en) Peptide for inhibiting binding of amylospheroids (aspd), and evaluation and screening method
WO2019179985A1 (en) Inhibitors of mint and uses thereof
Minami et al. Research article ApoE mimetic peptide decreases Aβ production in vitro and in vivo